The results of the POISE Trial were published in 2008. POISE was a randomised controlled trial of 30-day treatment with extended-release metoprolol or placebo in 8351 patients with or at risk of ischaemic heart disease having non-cardiac surgery 7 , and provided compelling evidence for reconsideration of widespread implementation, as although beta-blockade decreased the risk of myocardial infarction (MI) by 30%, it increased the risk of stroke by 50% and death by 25%. The authors concluded that "patients are unlikely to accept the risks associated with perioperative extended-release metoprolol" 8 .
The aim of the present study therefore was to explore the use of and effectiveness of perioperative beta-blockade before and after the release of the POISE Trial results. Our hypothesis was that knowledge of the results of the POISE Trial would change the effective use of perioperative betablockade; that is, that perioperative beta-blockade would increase if POISE showed improved outcomes without increased risk and would decrease if POISE showed no benefit and/or increased risk. We also explored the incentives and barriers to initiation of perioperative beta-blockade by anaesthetists in high-risk non-cardiac surgery patients.
MATERIALS AND METHODS
We audited existing perioperative practices in the highest-recruiting centres participating in the POISE Trial in Australia and New Zealand. This study was approved by the ethics committees in each centre. Because this project was considered to be an audit of existing practices, patient consent was waived at all centres.
Recruitment to POISE closed in July 2007. The first cohort was collected after the close of POISE and prior to the first presentation of the results at the American Heart Association meeting in November 2007. The main paper was published in May of 2008 8 . Presentations of the results were made in the investigators' departments and to regional and national meetings. The second cohort was collected in August and September of 2008.
Data collection
All procedures were the same for patients in the first and second cohorts. All sequential eligible patients were identified using the same screening processes that were used in POISE, which were reviewing medical records and interviewing patients in pre-admission clinics, day-of-surgery admission areas, wards and emergency departments of each hospital. Inclusion criteria were comparable to POISE, but did not include the requirement for patient consent (essential for POISE) and included current beta-blocker treatment (an exclusion criterion for POISE). We included beta-blocked patients because we assumed that a strongly positive or negative POISE Trial result would influence perioperative beta-blocker management in these patients as well. Eligible patients were ≥45 years of age, undergoing non-cardiac surgery, had an expected length of postoperative hospital stay ≥24 hours for surgical reasons, and one or more of coronary artery disease, peripheral vascular disease, past history of stroke, past history of admission for cardiac failure or current admission for major vascular surgery. Perioperative care, including the dosage, timing and route of beta-blocker administration and any screening for MI, was at the discretion of patients' doctors in this observational study. No guidelines were provided by the investigators.
Data collection commenced prior to induction of anaesthesia for the index surgery and concluded at hospital discharge or postoperative day 7, as applicable. We collected identical data to that collected in POISE, including the same data definitions 7 . We also included an outcome of MACE defined as death, MI, stroke or non-fatal cardiac arrest.
Perioperative beta-blockade was defined as at least one dose of beta-blocker administered before or soon after induction of anaesthesia, as well as a prescription for beta-blocker for the duration of hospital admission. Administration of betablockers during anaesthesia only was not defined as perioperative beta-blockade. At the end of surgery, an investigator asked the anaesthetist to nominate their reasons for either initiating or not initiating perioperative beta-blockade in patients who were not already on beta-blockers as per the above definition using the following (one or more) alternatives:
A) Not initiating beta-blocker therapy 1. bradycardia and/or heart block 2. hypotension 3. bronchospasm 4. heart failure 5. drug interaction 6. patient too low-risk 7. surgery too low-risk 8. prior adverse reaction to beta-blocker 9. logistical issues 10. no evidence to support perioperative betablockade.
B) Initiating beta-blocker therapy 1. perioperative heart rate and blood pressure control 2. patient very high risk of perioperative cardiac event 3. evidence supports perioperative beta-blockade.
Additional reasons were recorded as text.
We defined the primary outcome of "effective perioperative beta-blockade" as a heart rate <65 bpm on at least 80% of recorded measurements, from induction of anaesthesia until hospital discharge or postoperative day 7 in patients prescribed perioperative beta-blockade (as defined above). We assumed that if the result of the POISE Trial was strongly positive, this would encourage careful titration of beta-blockers to heart rate and not just a prescription of a fixed dose. The target heart rate was based on evidence suggesting that heart rate control <65 bpm throughout the entire perioperative period is probably needed to lower the risk of MACE 9-12 . Baseline heart rate was defined as the last measurement before administration of premedication or induction of anaesthesia. The percentage of each time period that heart rate was <65 bpm was calculated by the investigators at each centre for anaesthesia, the post-anaesthesia care unit, the remainder of the operative day, each postoperative day until day 7 and for the total time from induction of anaesthesia to the end of postoperative day 7. We also did a secondary analysis for heart rate control up to 48 hours 11 . Postoperative outcomes were defined as secondary outcomes of the trial.
We calculated a priori that to observe a 50% increase in effective perioperative beta-blocker therapy in patients prescribed perioperative betablockers from 40% to >60% or a 50% decrease from 40% to <20%, we needed 260 patients in each cohort (type I error 0.05, type II error 0.20). An absolute change of 20% was considered to be the minimum that would demonstrate a significant change in practice implementation. Based on data from POISE screening, we estimated that these data could be collected in two six-week periods at the six participating hospitals.
Analyses
Distributions of continuous data were assessed using the Kolmogorov-Smirnov test. Continuous data were summarised using median (range or interquartile range) and compared using unpaired t-tests (normally-distributed data) or Wilcoxon rank-sum tests (skewed data). Categorical data were summarised using number (%) and compared using chi-squared tests or Fisher's exact tests (where expected value ≤5 for any cell). All analyses were conducted with Stata 10.1 (Stata Corporation,
Included patients n=633
Pre POISE Trial n=392 (62%)
Postoperative BB no=5 (4%) yes=115 (96%) 
RESULTS
The first cohort was enrolled between 24 September and 29 November 2007 (n=392) and the second cohort was enrolled between 14 August and 26 September 2008 (n=193) ( Figure 1 ). Patients in the first cohort were older, more likely to have known coronary artery disease, more likely to be smokers and more likely to be having emergency surgery than patients in the second cohort (Table 1) . Fifty percent of all patients were receiving betablocker therapy preoperatively. Beta-blocker therapy was initiated within one month of surgery in 12 (6.2%) patients in the first cohort and six (5.8%) in the second cohort, P=0.89; within seven days of surgery in six (1.5%) patients in the first cohort and three (1.2%) in the second cohort, P=0.78; and postoperatively in 26 (13%) patients in the first cohort and 16 (13%) in the second cohort, P=0.97. Beta-blocker therapy was initiated by an anaesthetist in nine (2.3%) patients in the first cohort and three (1.2%) in the second cohort, P=0.35. Sixteen patients receiving beta-blocker therapy preoperatively did not receive them postoperatively (11 in the first cohort and five in the second cohort, P=0.57).
The rate of effective perioperative beta-blockade (the primary outcome) was assessed in the patients who met our definition of perioperative betablockade (at least one dose of beta-blocker administered anytime before or soon after induction of anaesthesia, as well as a prescription for betablocker for the duration of hospital admission). Two hundred and ninety-seven patients receiving preoperative beta-blocker therapy and 12 patients having beta-blocker therapy initiated intraoperatively were therefore included (n=309). Effective betablockade for the whole of the perioperative period was achieved in 22 (11.5%) of these patients in the first cohort and seven (6%) of these patients in the second cohort, P=0.10. For the first 48 hours, these results were 18.3 vs 11.9%, P=0. 13. There was no difference between the two cohorts in the choice of 'no evidence' as a reason for not initiating beta-blockade (Table 2) . Anaesthetists were more likely to cite concern about bradycardia, bronchospasm and drug interaction as reasons for not initiating beta-blockade in the first cohort than in the second cohort.
Patients in the first cohort received a higher percentage of their prescribed beta-blockers postoperatively than patients in the second cohort but overall most patients received most of their prescribed beta-blockers ( Table 3 ). The percentage of patients with a heart rate of <65 bpm for at least 80% of the perioperative period (from the induction of anaesthesia until hospital discharge or postoperative day 7) was 7.4% in the first cohort and 4.2% in the second cohort, P=0.10. For the first 48 hours, these results were 13.3 vs 9.1%, P=0.12. The median percentage time that heart rate was <65 bpm during the perioperative period was 6.4% (interquartile range 0 to 35%) in the first cohort and 6.0% (0 to 27%) in the second cohort, P=0. 19 . For the first 48 hours, these results were 8.8% (0 to 45%) vs 5.4% (0 to 40%), P=0.15. Patients in the first cohort were more likely to die, suffer significant postoperative bradycardia or hypotension Results are presented as number (%). * More than one reason was chosen for some patients. and be investigated with electrocardiography and troponin assays than patients in the second cohort, but were no more likely to have a MACE (Table 3) . Effective heart rate control for the whole perioperative period was achieved in 29 (9%) patients on perioperative beta-blockers and 10 (3%) patients not on perioperative beta-blockers, P=0.001. For the first 48 hours these results were 16.3 vs 7.2%, P <0.0001. Heart rate was controlled during anaesthesia in 137 (44%) patients on perioperative beta-blockers and 89 (27%) of patients not on perioperative beta-blockers (P <0.0001). Patients on perioperative betablockers were less likely to die than patients who were not on perioperative beta-blockers (3 vs 8%; P=0.007) ( Table 4 ). Patients with effective heart rate control were more likely to have significant bradycardia than patients without effective heart rate control (49 vs 21%; P <0.0001) ( Table 5 ).
DISCUSSION
In this study we attempted to demonstrate the effect of the POISE Trial on practice. Necessarily, the study was designed before the first cohort was collected and before the POISE Trial results were available. The hypothesis therefore needed to accommodate an increase or decrease in effective perioperative beta-blockade. We chose to study effective beta-blockade rather than just administration of beta-blockers, because we assumed that a strongly positive result would encourage careful titration of beta-blockers perioperatively.
We found that the rate of effective perioperative (and 48 hour) beta-blockade was low before and after publication of the POISE Trial results. Had the POISE Trial results been strongly positive, a substantial increase in perioperative beta-blockade could have been anticipated. However, the controversial and difficult-to-interpret results of POISE and the limitations of our study make drawing any firm conclusion difficult. Before the POISE Trial, clinical practice was strongly informed by two small clinical trials that reported significant benefits of perioperative beta-blockade with little apparent risk 1,2 , and by influential clinical practice guidelines 13 . However, a systematic review of all relevant perioperative beta-blocker trials reported a non-significant decrease in the incidence of cardiac events and an increased risk of bradycardia and hypotension in patients on beta-blockers 4 . This systematic review underpinned the rationale for POISE 7 and was widely discussed during site initiation for the trial. In our first cohort, in-frequent initiation of perioperative beta-blockade by anaesthetists and a low rate of effective betablockade is consistent with the view that there was insufficient evidence.
In the POISE Trial, metoprolol was associated with a decreased risk of non-fatal MI (4.2 vs 5.7%; P=0.002) but an increased risk of stroke (1.0 vs 0.5%; P=0.005) and death (3.1 vs 2.1%; P=0.03) compared with placebo. In a meta-analysis included in the main POISE paper, the pre-POISE relative risk of stroke had been 2.98 (95% confidence interval 0.74 to 12.0) whereas, after adding the results from the POISE trial, the post-POISE risk was 2.19 (1.06 to 4.50); the confidence intervals narrowed by a three-fold increase in the number of events 8 . The POISE Trial illustrated that large trials to determine the risks as well as the benefits of a treatment are essential 14, 15 , but raised more questions than it answered for clinicians contemplating perioperative beta-blockade. Vigorous discussion followed, which centred on the use of a high, fixed dose of longacting beta-blocker, without titration to heart rate in individual patients [16] [17] [18] [19] [20] [21] . Some concluded that the risk/benefit ratio for beta-blockade in the context of the POISE Trial did not favour their use [17] [18] [19] [20] , while others concluded that the benefits of beta-blockade might be retained and the adverse effects avoided by a lower starting dose and dose-titration 16, 22 . In our second cohort, the rate of effective perioperative (and 48 hour) beta-blockade was still low, and initiation of beta-blockade by our anaesthetists remained uncommon. This result is difficult to interpret for the reasons outlined below. The inclusion criteria for the POISE study and our study were different, with ours including patients already taking beta-blockers. Nevertheless, patients were at high risk of perioperative cardiac events and the rates of death, MI and stroke were similar to those reported in the POISE Trial 8 . We assumed that anaesthetists would generalise the results of the POISE Trial to a wider circle of perioperative patients (including those already on beta-blockers), and ensure that these patients received or did not receive beta-blockers (depending on the results). We also assumed that, if the POISE result was strongly positive, that anaesthetists would ensure that beta-blockade was effective in their patients with careful titration to heart rate. These assumptions may have been assessable if POISE had been strongly positive and beta-blockade initiation and/or effective betablockade had have increased in the beta-blocker naïve or all patients. However, we are unable to assess these assumptions because the rate of beta-blockade was so low in the first and second cohorts.
In addition, there were significant differences between the two cohorts at baseline. Patients in the first cohort were older and more likely to have ischaemic heart disease than patients in the second cohort, which may have influenced initiation of beta-blockade by anaesthetists in each group.
As mentioned above, the rates of effective perioperative beta-blocker therapy in patients prescribed perioperative beta-blockers in the first and second cohorts were much lower than we anticipated, limiting the power of our study. Therefore, 'no effect of the POISE Trial' is a valid explanation for our primary result. We considered an absolute change of 20% to be the minimum that would demonstrate a significant change in practice. This is a wide range for uncertainty and did not accommodate smaller changes. In addition, other events that were not measured could also have occurred between the two study periods that may have affected the results. Finally, our study was not designed to assess differences in the rates of adverse postoperative outcomes in patients who were and were not beta-blocked, and who had or did not have effective heart rate control (there were secondary exploratory analyses and due to the large number of comparisons, a type I error is possible). In any case, the baseline characteristics of the two groups were significantly different as mentioned above.
We assumed that the participating anaesthetists were well aware of the uncertainty regarding perioperative beta-blockade before POISE, and the results and commentary on the POISE Trial. This high level of knowledge may limit the generalisability of our study, as anaesthetists with less in-depth knowledge of the subject and no involvement in POISE may have been more inclined to implement beta-blockade before the results of the POISE Trial became known, based on widely promulgated expert opinions and guidelines 13 . Even for our anaesthetists, the 'take-home' message from POISE may not have been clear-cut, resulting in variations in practice. It is difficult to predict how individual patients and their doctors would decide between a potential decreased risk of MI and a potential increased risk of stroke and death. We assume that patients and doctors would generally decide not to implement beta-blockade on this basis. However, our anaesthetists may not have been as informed about the benefits and risks of beta-blockade as we anticipated or may not have been enabled to prescribe them in either cohort.
'No evidence' was the main reason given (apart from pre-existing beta-blocker therapy) for not initiating treatment. It is unclear however, whether anaesthetists citing 'no evidence' meant 'no evidence of benefit' or 'no evidence of an adequate risk/ benefit ratio', because concern about hypotension was not different between the two cohorts and we did not evaluate concern about stroke. The decreasing concern about bradycardia and bronchospasm in the second cohort may have reflected the different risk profile for patients in the second cohort or increased confidence about treating patients at risk of these complications based on reassurance from the main POISE publication. The lower incidence of bradycardia and hypotension in the second cohort may indicate less aggressive or better titrated beta-blocker therapy after POISE or the lower risk profile of the patients in the second cohort.
